erlotinib hydrochloride has been researched along with erythromycin in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (erythromycin) | Trials (erythromycin) | Recent Studies (post-2010) (erythromycin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 14,524 | 1,138 | 1,926 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | erythromycin (IC50) |
|---|---|---|---|
| 30S ribosomal protein S6 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S7 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L15 | Escherichia coli K-12 | 1.156 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.045 | |
| 50S ribosomal protein L10 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L11 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L19 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L1 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L20 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L27 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L28 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L29 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L31 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L32 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L33 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L34 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L35 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L36 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S10 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S11 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S12 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S13 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S16 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S18 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S19 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S20 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S2 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S3 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S4 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S5 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S8 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S9 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L13 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L14 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L16 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L23 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S15 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L17 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L21 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L30 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L6 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S14 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S17 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S1 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L18 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L2 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L3 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L24 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L4 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L22 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L5 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S21 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L25 | Escherichia coli K-12 | 1.156 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.039 | |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | 1.156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barletta, E; Cusano, F; Ferrara, G; Ingordo, V | 1 |
| Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C | 1 |
1 trial(s) available for erlotinib hydrochloride and erythromycin
| Article | Year |
|---|---|
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Erythromycin; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2014 |
1 other study(ies) available for erlotinib hydrochloride and erythromycin
| Article | Year |
|---|---|
Erlotinib-induced pustular eruption.
Topics: Acneiform Eruptions; Administration, Cutaneous; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythromycin; Gels; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |